title: Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant.
abstract: OBJECTIVE
  This retrospective analysis was aimed at evaluating the effectiveness of treatment of persistent diabetic macular edema with intravitreal injections of 0.7 mg dexamethasone implant Ozurdex. The study comprised three male patients (6 eyes).
  
  
  RESULTS
  The average thickness of the retina at baseline was 632  μm, the medial BCVA was 0.8 logMAR, and corrected intraocular pressure was 13.7 mmHg. The maximum decrease in mean retinal thickness was observed at four weeks following the treatment and was 365  μm (-267  μm) and visual acuity improved by an average of two lines and was 0.6 logMAR. The largest increase in mean retinal thickness to average of 528  μm (+164  μm) occurred at 16 weeks and the average BCVA was 0.614 lines BCVA logMAR. In one eye, there was a steroid cataract development after the third dose of dexamethasone implant of 0.7 mg.
  
  
  CONCLUSIONS
  The intravitreal dexamethasone implant treatment of patients with persistent diabetic macular edema in whom laser photocoagulation proved to be ineffective and as a result they required a monthly injection of anti-VEGF factors (Ranibizumab, Bevacizumab) may be a good alternative to extending the interval of injections. However, reinjections involve a high risk of developing poststeroid cataracts, which is not without significance in middle-aged patients.
authors.affiliation: Diagnostic and Microsurgery Center of the Eye LENS, 3a Budowlana Street, 10-424 Olsztyn, Poland.
authors.forename: Dominik
authors.initials: D
authors.lastname: Zalewski
authors.affiliation: Department of Anesthesiology and Intensive Care Medicine and Department of Ophthalmology, Medical University of Gdańsk, 17 Smoluchowskiego Street, 80-952 Gdańsk, Poland.
authors.forename: Dorota
authors.initials: D
authors.lastname: Raczyńska
authors.affiliation: Department of Ophthalmology, Medical University of Gdańsk, 17 Smoluchowskiego Street, 80-952 Gdańsk, Poland.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Raczyńska
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002386:Cataract / Q000139:chemically induced; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012160:Retina / Q000187:drug effects; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003907:Dexamethasone; D000069579:Ranibizumab